Guerbet, announced the first production batch has been manufactured and released for Elucirem™ (gadopiclenol) injection following FDA approval on September 21, 2022, after priority review.4  This next generation GBCA from Guerbet, highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older. Elucirem™ (Gadopiclenol) injection is used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).  GBCAs improve the contrast between lesions and surrounding tissues by accelerating the relaxation of protons interaction with gadolinium atoms.  Gadopiclenol, the active drug substance of Elucirem™, has been designed to enable twice as much interaction, resulting in the relaxivity among all non-specific GBCAs.5 This allows use at half the conventional gadolinium dose to reveal high quality images. Elucirem is manufactured by Liebel-Flarsheim™ Company LLC, a Guerbet Group company, in Raleigh, North Carolina and is now available for order.